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DuetothecallforfastKRASmutationstatusanalysisfortreatmentofpatientswithmonoclonalantibodiesformetastaticcolorectal
cancer, sensitive, economic, and easily feasible methods are required. Under this aspect, the sensitivity and speciﬁcity of the
SNaPshot analysis in comparison to the commonly used DNA sequencing was checked. We examined KRAS mutations in exon 2
codons 12 and 13 with DNA sequencing and SNaPshotanalysis in 100 formalin-ﬁxed paraﬃn-embedded tumor tissue samples of
pancreatic carcinoma,colorectal carcinoma,and nonsmallcell lung cancer specimens of the primary tumor or metastases.40% of
these samples demonstrated mutated KRAS genes using sequencing and SNaPshot-analysis;additional ﬁve samples (45/100) were
identiﬁed only with the SNaPshot. KRAS mutation detection is feasible with the reliable SNaPshot analysis method. The more
frequent mutation detection by the SNaPshot analysis shows that this method has a high probability of accuracy in the detection
of KRAS mutations compared to sequencing.
1.Introduction
Colorectal cancer, nonsmall cell lung cancer (NSCLC), and
pancreatic carcinomas are three of the most frequent causes
of cancer mortality in the world.
Established therapies are targeted on the epidermal
growth factor receptor (EGFR), such as Panitumumab
[1–4]a n dC e t u x i m a b[ 5–8] (two monoclonal antibodies)
treatment for metastatic colorectal carcinoma, Geﬁtinib for
NSCLC, or Erlotinib for NSCLC and for pancreatic car-
cinoma. Treatment success using Cetuximab and Pani-
tumumab for treatment of metastatic colorectal cancer
depends on a nonmutated KRAS gene; the treatment is inef-
fective if the KRAS gene has any mutations [1, 5, 6, 8],
which leads to an activated G-protein even in absence of
the ligand, like the epidermal growth factor [9, 10]. This
results in further malignant proliferation of the cells despite
treatment.
Two codons in the KRAS gene are mainly known to
generate alternated proteins that are constitutively activated
without the signal of a ligand bound to the EGFR. This are
the codons 12 and 13 in the exon 2 of the KRAS gene [9, 10].
Both codons encode the amino acid glycine in the wild type
protein. Replacement of one of the ﬁrst two bases leads in
both codons toan amino acidexchange in the KRASprotein,
resulting in resistance of the tumor to the above-described
treatment.
Replacement of glycine leads to resistance of the GAPs,
which are proteins causing the hydrolysis of KRAS bound
GTP to GDP. The inability of GAPs to eﬀect the GTP hydrol-
ysis in mutated KRAS leads to a constitutive active protein
[10].
Up to now KRAS mutation analysis is mainly performed
by DNA sequencing [5] and commercialised test systems by
DNA-DNA hybridisation (e.g., Chipron, Berlin, Germany),2 Gastroenterology Research and Practice
pyrosequencing [11], or the Therascreen: K-RAS Mutation
Kit from Qiagen [12] based on Real-time PCR technologies.
In consideration of an inhomogeneous genotype concerning
the KRAS mutation status of the tumor cells, more sensitive
detection methods are required. If the tumor has a small
content of KRAS mutated cells, not detectable by DNA
sequencing, anti-EGFR therapy probably fail to have an anti-
proliferating eﬀect on these cells.
T h eS N a P s h o ta n a l y s i si sr e g a r d e da sm o r er e l i a b l ei n
comparison to common DNA sequencing [8]a n da b l et o
detect tiny allele amounts of mutated KRAS. The aim of this
study is to test the SNaPshot method in comparison to DNA
sequencing for screening of KRAS mutation.
2.Materialsand Methods
2.1. Tumor Tissue Samples and DNA Extraction. Our study
was carried out using tumor tissue samples from diﬀerent
sources: normal diagnostic cases of NSCLC (n = 41, 33
surgically resected specimens and 8 biopsy specimens)
and colorectal carcinoma (n = 20, 18 surgically resected
specimens and 2 biopsy specimens), archived pancreatic
carcinomas (n = 19, 8 surgically resected specimens and
11 biopsy specimens), and FFPE (formalin-ﬁxed paraﬃn-
embedded) material of colorectal cancer specimens on slides
from an interlaboratory comparison of KRAS mutation
screening in spring 2008, organised by the German Society
of Pathology. All specimens were made anonymous and
examined by a pathologist, who choose a tumor-area with
at least 70% of vital tumor cells for DNA-isolation. Weichert
et al. [13] mentioned that specimens habroring fewer than
10% tumor cells showed lower mutation rates regardless of
the method used.
The tumor tissue was ﬁxed on slides (3μmt h i c k ) ,
deparaﬃnated, and the tissue material was microdissected
for DNAextraction using the QIAamp DNAMicro Kit (Qia-
gen, Hilden, Germany). Tissue material from the interlabo-
ratory comparison on slides was identiﬁed by microscopy as
tumor and normal tissue and DNA was extracted from both
tissue samples (n = 20).
2.2. Ampliﬁcation Step before SNaPshot and Sequencing
Analysis. After extraction of the genomic DNA from the
samples, the KRAS gene exon 2 was ampliﬁed by PCR (with
HotStarTaq DNA Polymerase, Qiagen, Hilden, Germany)
with the following primer set: 5 -AAGGCCTGCTGAAAA-
TGACTG-3  and 5 -CAAAGAATGGTCCTGCACCAG-3 
[8]. After checking the ampliﬁcation product on an agarose
gel, the PCR reaction was puriﬁed with the MinElute PCR
Puriﬁcation Kit (Qiagen, Hilden, Germany) and used for
sequencing and the SNaPshot reaction.
Each PCR reaction had a 25μL volume and contained:
the above-mentioned primer set with a concentration of
400nM, 1 × PCR buﬀer, 2.5mM MgCl2,0 . 1μg/μLB S A ,5
units of the polymerase, 200μM of each deoxynucleotide,
and 100ng of genomic DNA. The PCR reaction ran with the
following program: 95◦C initial denaturation for activating
the HotStarTaq DNA Polymerase for 15 minutes, step 2
denaturation at 94◦C for 30 seconds, step 3 annealing of the
primer to the template at 55◦C for 30 seconds, and step 4
30 seconds at 72◦C for primer extension. Steps 2 to 4 were
repeated 45 times followed by a ﬁnal extension step at 72◦C
for 10 minutes, then the PCR reaction was cooled down to
8◦C. One PCR preparation is used for sequencing reaction
and the SNaPshot analysis.
2.3. DNA Sequencing. The puriﬁed DNA was used as a
template for the sequencing reaction with the BigDye Termi-
natorv1.1 Cycle Sequencing Kit (Applied Biosystems, Forster
City, CA). The sequencing reaction was performed with the
3  kRAS primer (5 -CAAAGAATGGTCCTGCACCAG-3 )
with the following program on the thermocycler: 1 minute
for an initial denaturation of the DNA at 96◦C, followed by
25 cycles of a 10-second denaturation at 96◦C, annealing of
the primer at 50◦C for 5 seconds, and the extension step at
60◦C for 4 minutes. After this program, the samples were
stored at 4◦C.
The capillary electrophoresis was performed on the
3130 Genetic Analyzer, and the obtained electropherogram
(Figure 1(b)) was analysed with ﬁnchTV (Geospiza, Seattle,
WA, USA) software (receivable online).
2.4. SNaPshot. The primers used for SNaPshot were imple-
mented accordingly to the algorithm of Di Fiore et al. [8]:
codon 12 position 1; 5 -AACTTGTGGTAGTTGGAGCT-
3 , codon 12 position 2; 5 -GATCGTACTTGTGGTAGT-
TGGAGCTG-3 , codon 13 position 1; 5 -GATCGATCG-
ATCTTGTGGTAGTTGGAGCTGGT-3 , codon 13 position
2;5 -GATCGATCGATCGATCGATGTGGTAGTTGGAGC-
TGGTG-3 . These primers anneal one nucleotide position
before the potential mutated base on the template DNA
and in the course of polymerization with the SNaPshot
Multiplex Kit (Applied Biosystems, Forster City, CA, USA),
only this nucleotide is added as di-deoxy nucleotide to
the primer sequence. A further polymerization is excluded,
because of the lacking 3 -hydroxyl group on their nucleotide
deoxyribose.
T h eS N a P s h o tr e a c t i o nt o o kp l a c ei na1 0 μL volume
with 1μL PCR product, 5μL SNaPshot Multiplex Master
Mix, and a 2μM concentration of each primer. The program
on the thermocycler was 25 cycles of denaturation at 96◦C
for 10 seconds, primer-annealing at 50◦C for 5 seconds,
and an extension step at 60◦C for 30 seconds then cooling
down to 4◦C. After the SNaPshot reaction was performed,
a puriﬁcation step was necessary to eliminate interfering-
free nucleotides. Adding 1μL shrimp alkaline phosphatase
(1U/μL) (NEB, Ipswich, MA) and incubating for 1 hour at
37◦C, followed by a denaturation step at 75◦Cf o r1 5 m i n ,
clean up the SNaPshot reaction for capillary electrophoresis
on the 3130 Genetic Analyzer (Applied Biosystems, Forster
City, CA).
For capillary electrophoresis an internal DNA sizing lad-
der was used, the GeneScan-LIZ 120 Size Standard (Applied
Biosystems, Forster City, CA). No further analysis program
is necessary; the relevant data can be read directly from the
electropherogram [8]( e . g . ,F i g u r e1(a)).Gastroenterology Research and Practice 3
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Figure1:TheelectropherogramsoftheSNaPshotanalysis(a)andtheDNAsequencing(b)ofthesametumortissuesample.Themutationof
codon 12 position 2 guanine to adenine transition is deﬁnitely visible in the SNaPshotanalysis.In the sequencing analysis,the adenine-peak
is hardly distinguishable from the background.
2.5. Statistical Analysis. The sensitivity and the speciﬁcity
of SNaPshot analysis in KRAS mutation screening in
comparison to common DNA sequencing was tested. The
DNA sequencing was assumed as standard method with a
speciﬁcity and sensitivity of 100%.
3.Results
In 45 (45%) out of 100 analysed tissue samples, a KRAS
mutation in codon 12 or 13 were detected. 40 (88.9%)
of these mutated KRAS genes were discovered by DNA
sequencing and SNaPshot, a further ﬁve mutations (11.1%)
were only detectableby SNaPshot. This resultsina sensitivity
of 100% with a conﬁdence interval of 95% [91.2% to 100%]
and a speciﬁcity of 91.7% with a conﬁdence interval of 95%
[81.6% to 97.2%], respectively.
Figure 1 shows an example of a mutation detection
by SNaPshot but not by sequencing. The analysed cancer
specimens were dissected in NSCLC, colorectal carcinoma,
and pancreatic carcinoma. For NSCLC, we detected in 15/41
(36.6%)KRAS-mutatedcancertissue samples, in6/20(30%)
KRAS mutations in colorectal specimens, in 14/19 (73.7%)
pancreatic tumor samples, and in 9/20 (45%) colorectal
tumor samples from the interlaboratory comparison.
The type of mutations in KRAS exon 2 codons 12 and 13
can be grouped in transitions and transversions. Transition
mutations of KRAS exon 2 codons 12 and 13 occur in the
majority (71.4%) of pancreatic carcinoma. NSCLC KRAS
mutations mainly occur as transversions (78.6%) and KRAS
mutations of colorectal carcinomas are evenly distributed
as transition and transversion. In the NSCLC samples,
G37T, G38A, G35T G34T, and G35A occur. The colorectal
specimens show G34A, G38C, G35A, and G34T mutations.
The pancreatic carcinomas show three diﬀerent types of
KRASmutations: G35A,G34C,and G35T.The kind of KRAS
mutations found in the tissue samples are explicitly listed in
Figure 2 with the percentage of the total mutation number.
4.Discussion
The given percentage of KRAS mutation in NSCLC is 21–
43% [4, 14] and 33% [15] for colorectal cancer and for
pancreatic carcinomas 75–82.4% [15, 16]. KRAS mutation
frequency in our examinations showed 36.6% for NSCLC
and30%forcolorectalcancer.73.7%ofmutatedKRASgenes
in pancreatic carcinoma is in accordance with previously
described data [15].
With regard to the present prerequisite of KRAS muta-
tion screening before a therapy with Panitumumab and
Cetuximab, KRAS is a powerful molecular marker in cancer
diagnostics [1, 5]. The molecular cancer diagnostic is on
the way to aﬀord a more individualised therapy for these
patients. This aim makes a molecular screening of the tumor
necessary, which reveals the cancer characteristics correlated
to the response to a chemotherapy.
Severalstudiesindicate greater beneﬁt from a Cetuximab
therapy for EGFR expressing metastatic colorectal cancer
patients with KRAS wild type [5–7]. Cetuximab in the ﬁrst-
line treatment combined with Oxaliplatin, Leucovorin, and
Fluorouracil increases the overall response rate in patients
with metastatic colorectal cancer [17].
Next to the important prediction of drug response
for metastatic colorectal carcinomas, KRAS mutations may
also be decisive for drug decision in NSCLC in regard
to Erlotinib or Geﬁtinib, because these kinase inhibitors
seem to be ineﬀective in carcinomas with KRAS mutation
[12, 16, 17]. Eberhard et al. [14]s h o w e das h o r t e rm e d i a n
time to progression and survival in patients treated by
Erlotinib and Cisplatin in case of mutated KRAS compared
to patients receiving Cisplatin alone. KRAS does not seem
to be a predictive factor [15] in a study with Geﬁtinib and
chemotherapy for advanced colorectal cancer.
Particularly with regard to the expanding ﬁeld of KRAS
mutation status detection, it is necessary to determine the
allele status in a reliable way. Therefore, knowledge of the
KRAS gene mutation status is essential before the decision
is made to treat a cancer patient using EGFR-targeted
Panitumumab and Cetuximab therapy. Also considering the
enormouscostsandsideeﬀectsofthetherapy,theKRASgene
mutation analysis is necessary.
KRAS mutation can be screened in several ways: DNA
sequencing, commercialised test systems by DNA-DNA
hybridisation and SNaPshot analysis [8]. In this paper, we
comparethecommonsequencinganalysis andtheSNaPshot,
which is regarded to be more reliable [8]. Our results do
reveal a better mutation detection, shown by the statistical
analysis. The sensitivity reached 100% and the speciﬁcity
91.7%, implying a high probability of accuracy of the
SNaPshot.4 Gastroenterology Research and Practice
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Figure 2: Delaminating of KRAS genotype of diﬀerent tissue specimen. This picture shows the percentage of mutation types found in the
particular kind of cancer specimens. The legend under the picture explains the colours used for the diﬀerent genotypes.
To ensure a positive mutation result and avoid false
positive results, it is also recommended to run, next to a
nucleic acid-free control sample (“water-control”), a KRAS
wildtype control, with the known wildtype KRAS sequence.
The SNaPshot analysis shows a few advantages in addi-
tion to the enhanced reliability. It is less expensive and more
rapid than the sequencing analysis (SNaPshot 11C versus
19C for DNA sequencing) and could be analysed with-
out additional software, except the Genemapper program
(Applied Biosystems, Forster City, CA, USA). Considering
these qualities, the SNaPshot analysis could replace DNA
sequencing in KRAS mutation screening.
The Therascreen: K-RAS Mutation Kit from Qiagen [12]
uses a combination of ARMS-technology and Scorpions-
primers, so it is possible to determine mutations of only 1%
mutated allel in the background of wildtype genotype. But
the kit could detect only 7 possible mutations types of the
KRAS gene,buta whole of12 mutationscan occurin codons
12and13.Inouranalysis, wedetected2mutationstypes,one
inacolorectalcarcinomaspecimen, which wouldbedetected
as false negative with the therascreen kit.
The KRAS mutations can be subdivided in transversions
and transitions. Both events lead to the exchange of the
amino acid glycine to another amino acid in the protein. A
transition is a replacement of one purine base to the other
or one pyrimidine base to another, and a transversion is a
replacement from a purine base to a pyrimidine base or vice
versa. The occurrence of transition and transversion is not
evenly distributed in these three diﬀerent kinds of tumor
tissue. Transversions appear more frequently in NSCLC and
transitions more frequently in pancreatic carcinoma. Both
mutation types occur evenly in colorectal carcinoma. An
unequal frequency of occurrence of mutation types suggests
diﬀerent conditions in these three kinds of tumor. For a
transition, just the addition or removal of an amino group is
necessary. For a transversion, the base has to be removed and
the new base has to be added. Riely et al. showed transition
of the KRAS gene in lung cancer occurring more frequent
in never smokers than in former or current smokers. This
could imply that transversion mutations are associated with
smoking [18].
For protocol of the KRAS detection only by SNaPshot,
is it feasible to shorten the puriﬁcation step of the PCR
and use only a SAP/EXO degradation of interfering nucleic
acids. Depending on the size of the PCR product, the
SNaPshot is expandable to newly identiﬁed SNPs, simply
by adding a suitable primer and PCR product to the
reaction. This is a less expensive method to analyse SNPs in
other genomic regions by just adding primer for the PCR
and the SNaPshot reaction. However, the data cannot be
reanalysed for unconsidered sequences. The SNaPshot has to
be repeated with additional primers.
Tiny proportions of mutated KRAS alleles can easily be
screenedbytheabove-mentionedmethods.IneventofKRAS
mutation, therapy with monoclonal antibodies Cetuximab
and Panitumumab should be withdrawn [5, 11]. Tiny allele
amounts of mutated KRAS suggest a majority of wild type
cells concerning the KRAS gene in the tumor. The lack of
quantiﬁcationofKRASmutationallelesmaydeprivepatients
of a treatment, which could be targeted on tumor cells with
intact KRAS gene. Therefore, KRAS mutation detection with
SNaPshot could have a more enhanced role in response
prediction of therapy depending on which response can be
expected due to the amount of mutated KRAS allele in the
tumor.Gastroenterology Research and Practice 5
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